Paratek Pharmaceuticals — Investor Presentation (January 2017)
48 slides from Paratek Pharmaceuticals's investor presentation, Jan 9, 2017
Slide 1: Corporate Overview January 2017
Corporate Overview January 2017 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation
Slide 3: Omadacycline: Proven Antibiotic with Blockbuster Potential
Omadacycline: Proven Antibiotic with Blockbuster Potential Positive Phase 3 Data: Skin Infections CABP Phase 3 Study: Data Expected 2Q 2017 Oral-Only Skin Study Would Accelerate Community Adoption: Data Expected 2Q 2017 Anticipated NDA Filing: 1H 2018 Proof-of-Concept cUTI Phase 2 Study (enrolling a
Slide 4: Experienced Senior Management Team
Evan Loh, MD President CCO & CMO Led Tygacil Development Experienced Senior Management Team Michael F. Bigham Chairman & CEO Evan Loh, MD President, Led Tygacil Development Doug Pagán Chief Financial Officer Adam Woodrow Chief Commercial Officer Led Tygacil Commercialization William Haskel SVP, Gene
Slide 5: Potent New Class of Antibiotic: Aminomethylcyclines
Potent New Class of Antibiotic: Aminomethylcyclines Restoring Tetracycline Efficacy by Overcoming Resistance 9-Position Modification: Overcomes Ribosomal Protection 7-Position Modification: Overcomes Efflux Pump
Slide 6: Omadacycline: Broad Spectrum Multi-Indication Oral Targeting Big 3 Community Infections
Omadacycline: Broad Spectrum Multi-Indication Oral Targeting Big 3 Community Infection Indications (1) Pallin DJ, Clinical Infectious Diseases 2009 (2) Decision Resources, 2012 (3) AMR Data 2015 IMS analytics link MIDAS ABSSSI CABP UTI Broad Spectrum for Community-Acquired Resistance Well-tolerated,
Slide 7: Late Phase Development Pipeline Approaching Potential Commercialization
Late Phase 3 Development Pipeline Approaching Potential Commercialization Research Preclinical Phase 1 Phase 2 Phase 3 NDA Commercial Rights Omadacycline Sarecycline (U.S.) (ex-U.S.) (Global) CABP (Oral & IV) – QIDP + SPA cUTI (Oral & IV) – QIDP Acute Sinusitis – (Oral) Inflammatory Acne Vulgaris AB
Slide 8: Omadacycline Clinical Update
Omadacycline Clinical Update
Slide 9: Completed Phase 3 ABSSSI Study Design
FDA Primary Endpoint Early Clinical Response: > 20% reduction in lesion size 48 to 72 hours after first dose of study drug in the modified Intent to Treat (mITT) population EMA Co-Primary Endpoints Clinical response at post treatment evaluation (PTE) in the mITT population Clinical response at post
Slide 10: Omadacycline Achieved Primary Endpoints for Both FDA and EMA
Omadacycline Achieved Primary Endpoints for Both FDA and EMA EMA Co-Primary Endpoints Delta (95% CI) -0.7 (-6.3, 4.9) Delta (95% CI) +2.5 (-3.2, 8.2) Delta (95% CI) +2.8 (-1.0, 6.9) FDA Primary Endpoint
Slide 11: ITT Population: High Rate of Completion
Omadacycline Linezolid All Subjects ITT 329 326 655 Completed study drug treatment n (%) 296 (90.0) 288 (88.3) 584 (89.2) Prematurely discontinued study drug 33 (10.0) 38 (11.7) 71 (10.8) Adverse Event 6 (1.8) 7 (2.1) 13 (2.0) Lost to Follow-up 5 (1.5) 9 (2.8) 14 (2.1) Withdrawal by subject 8 (2.4)
Slide 12: Safety Population Profile: Low Rate of Adverse Events
Omadacycline (N=323) Linezolid (N=322) Subjects with any TEAE n (%) 156 (48.3) 147 (45.7) Nausea(1) 40 (12.4) 32 (9.9) Infusion site extravasation(2) 28 (8.7) 19 (5.9) Subcutaneous abscess 17 (5.3) 19 (5.9) Vomiting 17 (5.3) 16 (5.0) Cellulitis 15 (4.6) 15 (4.7) Headache 10 (3.1) 13 (4.0) ALT increa
Slide 13: Omadacycline Penetrates Lung Tissue and Pulmonary Macrophages
Omadacycline Penetrates Lung Tissue and Pulmonary Macrophages Supports Potential for Efficacy in CABP Phase 3 Trial
Slide 14: Ongoing Phase 3 CABP Study Design
Ongoing Phase 3 CABP Study Design SPA Approved: IV to Once-Daily Oral FDA Primary Endpoint Early Clinical Response: improvement in > 2 of 4 subject symptoms 72 to 120 hours after first dose of study drug in the Intent to Treat (ITT) population EMA Co-Primary Endpoints Resolution of infection signs a
Slide 15: Ongoing Oral-Only Skin Study
FDA Primary Endpoint Early Clinical Response: > 20% reduction in lesion size 48 to 72 hours after first dose of study drug in the modified Intent to Treat (mITT) population EMA Co-Primary Endpoints Clinical response at post treatment evaluation (PTE) in mITT population Clinical response at post trea
Slide 16: Critical Need for a New Broad Spectrum Oral Antibiotic
Critical Need for a New Broad Spectrum Oral Antibiotic ABSSSI: High Resistance Rates to Generic Antibiotics Resistance rates to generic oral broad spectrum antibiotics used for community ABSSSI (9M RX in the U.S.)(6) Common ABSSSI pathogens >80% of all infections(2) TMP/SMX(4) Tetracycline(3) Clinda
Slide 17: Omadacycline Potentially Addresses Unmet Needs for UTI
Omadacycline Potentially Addresses Unmet Needs for UTI High Resistance Rates and Fluoroquinolone Safety Concerns Organisms (# Isolates) Levofloxacin Resistant(1) TMP-SMX Resistant(2) Amoxicillin-Clavulanic Acid Resistant(1) E. coli (>4100) 35.2% 39.3% 31.8% E. coli ESBL+ (>790) 76.7% 67.8% 70.2% E.
Slide 18: Completed Omadacycline Phase 1b UTI Study
Completed Omadacycline Phase 1b UTI Study Imminent Need to Replace Quinolones Group 1 (n=10) Dose 200 mg IV Day 1 Dose 300 Oral q24h Days 2-5 Screening (≤ 48 hours prior to randomization) End of Treatment (Day 6) Post Treatment Evaluation Follow-Up Group 2 (n=10) Dose 300 mg Oral q12h Day 1 Dose 300
Slide 19: UTI Phase 1b Study Provides Positive Proof-of-Principle
UTI Phase 1b Study Provides Positive Proof-of-Principle Leveraging PK/PD Omadacycline Levels in Urine Omadacycline Levels in Plasma Integrated PK/PD Data Informs Development Pathway
Slide 20: High Concentrations of Omadacycline in Urine Supports cUTI Pathway
High Concentrations of Omadacycline in Urine Supports Development of a cUTI Registration Pathway Day 5 Day 1 Likely Next Steps for cUTI Development: Phase 2 study Pyelonephritis Enrollment starting as early as 4Q 2017
Slide 21: Recently Completed Phase 1 & Manufacturing Milestones
Recently Completed Phase 1 & Manufacturing Milestones: NDA Filing Requirements and Timing Omadacycline Ph 1 Data Key Data Informs Completion Timing Multi-dose Oral PK Oral Loading Regimen 3Q 2016 UTI Ph 1b: PK/PD Proof-of-Principle UTI Efficacy Potential 4Q 2016 Lung BAL-PK Ph 1 Lung Penetration (CA
Slide 22: Omadacycline Commercial Opportunity
Omadacycline Commercial Opportunity
Slide 23: Rising Community Based Resistance Creates Demand for New Oral Agents
Rising Community Based Resistance Creates Demand for New Oral Agents(1) 9 The Drug Index (DRI) Shows the Rates of Resistance for UTI’s and SSTI’s, Two of the Most Common Infections in the U.S. Have Increased Significantly From 1999 to 2010
Slide 24: Scarcity of New IV/Oral Empiric Antibiotics in Development Today
Scarcity of New IV/Oral Empiric Antibiotics in Development Today Broad spectrum empiric IV/Orals, now generic Newer targeted agents typically IV hospital only What will replace the failing generic broad spectrum IV/Orals 2016-2020 ?
Slide 25: Omadacycline: Well Positioned for Blockbuster Potential
Omadacycline: Well Positioned for Blockbuster Potential Profile Similar to Best Selling Antibiotics Antibiotic Broad Spectrum Oral Frequency Favorable Tolerability Big 3(1) Indications 2010 Sales(3,4) Levofloxacin Once Daily 3 $3.4B Co-Amoxy clav Twice Daily 3 $2.8B Azithromycin(2) Once Daily 2 $1.8
Slide 26: Omadacycline Offers Healthcare System Significant Cost Savings
Care of patients with ABSSSI, CABP and UTI places a major financial burden on the U.S. healthcare system, largely due to hospitalization costs. Analysis suggest Omadacycline offers costs savings at prices between $2,000 - $7,500 per course Hospital Cost Savings: Reduced length of stay via early disc
Slide 27: 3.4M Addressable U.S. Patients
3.4M Addressable U.S. Patients 2nd Line Empiric Treatment After 1st Line Failure (1) AMR hospital anti-infectives guide 2015 (reflects hospital in-patients) (2) IMS NSP data combined with NDTI diagnosis code estimates 2015 (reflects community Rx; figures reduced by 25% to estimate patients with mult
Slide 28: Addressable U.S. Hospital Market
Addressable U.S. Hospital Market: Omadacycline IV & Oral Opportunities in the “Big Three” Indications ABSSSI Opportunity: 1st line treatment (Tx) failure, resistance suspected CABP Opportunity: 1st line Tx failure, resistance suspected UTI Opportunity: 1st line Tx failure (or repeated Tx), ESBL susp
Slide 29: 3.4M Addressable U.S. Patients
3.4M Addressable U.S. Patients 2nd Line Empiric Treatment After 1st Line Failure (1) AMR hospital anti-infectives guide 2015 (reflects hospital in-patients) (2) IMS NSP data combined with NDTI diagnosis code estimates 2015 (reflects community Rx; figures reduced by 25% to estimate patients with mult
Slide 30: Addressable U.S. Community Market
Addressable U.S. Community Market: Omadacycline Oral Opportunities in the “Big Three” Indications ABSSSI Opportunity: Initial treatment (Tx) failure, resistance suspected CABP Opportunity: Fluoroquinolone failure, resistance suspected UTI Opportunity: Initial Tx failure (or repeated Tx), ESBL suspec
Slide 31: Commercial Strategy in the U.S.
Years 1-2: Drive Trial and Early Use Hospital Formulary Acceptance Hospital Field Force: ~85 representatives Complementary MSL field force Years 2-3: Early Use Becomes Adoption Referral into community on oral in years 1-2 drives use more broadly into the community Oral-Only Indication Accelerates Co
Slide 32: Omadacycline CMC/Intellectual Property
Omadacycline CMC/Intellectual Property
Slide 33: Omadacycline Manufacturing
Omadacycline Manufacturing Robust Commercial-Scale Formulations and Process Established Both Oral Tablet and IV Manufactured at Commercial Scale Established Stability >3 Years at Room Temp for Both Oral and IV 3 Step Manufacturing Process Registration Lots Completed (n=3 Oral and IV): Produced at Co
Slide 34: Omadacycline IP Protection and Market Exclusivity
Omadacycline IP Protection and Market Exclusivity Strong IP Through 2028 Patent Term Extension Key Composition of Matter Patent Expires June 2023 US Data Exclusivity Possible 6 month pediatric extension 2000 2005 2010 2015 2020 2025 2030 Patent Issued File NDA Approval Protection through 2028 U.S. B
Slide 35: Sarecycline Overview
J PARATEK ~ PLL Sarecycline Overview Ss Se em, =
Slide 36: Sarecycline: Narrow-spectrum Tetracycline Antibiotic for Inflammatory Acne
Novel, narrow-spectrum antibiotic Demonstrated anti-inflammatory activity Does not cross Blood-Brain Barrier Favorable GI tolerability Once-daily Oral formulation Composition of Matter IP protection U.S. Base Composition of Matter: 2031 EU: 10 years of market exclusivity expected Sarecycline: Narrow
Slide 37: Sarecycline Late-Stage Development Progressing as Planned
(1) Allergan plc, “R & D Day ,” p. 48 November 4, 2015) (2) As reported by Allergan (3Q2016 earnings call) (2) IMS Sales data 2011 Sarecycline Late-Stage Development Progressing as Planned U.S. commercial rights: Allergan Ex-U.S. commercial rights: Paratek Phase 2 Trials met primary endpoints for ef
Slide 38: PRTK Financials
© PARATEK “ss PLL PRTK Financials
Slide 39: Near-Term Flow of Key Milestones: Phase Data and NDA Filings
Near-Term Flow of Key Milestones: Phase 3 Data and NDA Filings Omadacycline Events Estimated Timing ABSSSI Phase 3 Data: IV and Oral Positive Phase 3 Data UTI Phase 1b Data: Positive PK/PD Proof-of-Principle 4Q 2016 CABP Phase 3 Data: IV and Oral 2Q 2017 ABSSSI Phase 3 Data: Oral-Only 2Q 2017 Omadac
Slide 40: Key Financial Information
Key Financial Information Key Metrics – Unaudited 9/30/16(1) Pro forma(2) Total Cash, as Adjusted $120.8 million $140.8 million Total Debt, Net of Issuance Costs $19.6 million $39.6 million Basic Shares Outstanding, as adjusted 22,627,771 22,627,771 Stock Options, Restricted Stock Units, and Warrant
Slide 41: Omadacycline: Proven Antibiotic with Blockbuster Potential
Omadacycline: Proven Antibiotic with Blockbuster Potential Positive Phase 3 Data: Skin Infections CABP Phase 3 Study: Data Expected 2Q 2017 Oral-Only Skin Study Would Accelerate Community Adoption: Data Expected 2Q 2017 Anticipated NDA Filing: 1H 2018 Proof-of-Concept cUTI Phase 2 Study (enrolling a
Slide 42: Omadacycline Commercial Strategy - Back-up
Omadacycline Commercial Strategy -back-up
Slide 43: Omadacycline: New Broad Spectrum Oral for ABSSSI
Attribute Omadacycline(4) TMP/SMX(1,3) Tetracyclines(2,3) Clindamycin(2,3) Penicillins(2,3) Linezolid(2,3) MRSA Activity Streptococcus Activity Broad Spectrum Convenience of Dosing - - Favorable Oral Tolerability - - Limited Drug Interactions - - No Black Box Omadacycline: New Broad Spectrum Oral fo
Slide 44: ABSSSI Patient Journey
ABSSSI Patient Journey OMC Opportunity: Empiric Therapy When Resistance is Confirmed Total Outcome a AMR data (2015): 67.5% of patients never received confirmed pathogen (i.e.., empiric only); 42.8% receive agent with some MRSA coverage (vanc is majority) b AMR data (2015): Of patients never receivi
Slide 45: Omadacycline: New Broad Spectrum IV and Oral for CABP
Attribute Omadacycline(4) Quinolones(1,3) Macrolides(1,3) Penicillins (1,3) Cephalosporins(1,3) S.Pneumoniae H.influenzae Legionella S.Aureus inc MRSA Favorable Oral Tolerability Limited Drug Interactions Convenient Dosing No Black Box Omadacycline: New Broad Spectrum IV and Oral for CABP Promising
Slide 46: CABP Patient Journey
CABP Patient Journey OMC Opportunity: When Patients Have Failed 1st Line Quinolone Therapy Total Initial Tx High Risk/ Susp Resistb a AMR (2015) b Primary market research (est 18% of hospitalized CABP patients & 16.5% of community CABP patients are “high-risk” and suspected/confirmed to have a resis
Slide 47: UTI: No Effective Broad Spectrum Oral Approved Antibiotics
Attribute Omadacycline(4) Quinolones(1,3) TMP/SMX(2,3) Penicillins (1,3) E. coli Activity ESBL + Activity VRE Activity Renal Excretion Convenience of Dosing - Favorable Oral Tolerability - Limited Drug Interactions - No Black Box (1) JMI surveillance 2011, data on file (2) JMI Surveillance 2010, dat
Slide 48: UTI Patient Journey
UTI Patient Journey When Resistance Makes Quinolones No Longer an Option Total MDR E.Coli a AMR (2015) b IMS NSP (2015) c DRG Current Treatment: Gram Negative Infections (ID’s est ~20% failure rate for fluoroquinolones) d Primary market research (est 1-2% of community patients sent to ED/hospital du
Paratek Pharmaceuticals — Investor Presentation (January 2017) on 6ix